Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6314598 | 0.84 | TRPA1 (0.34) | TRPA1ATMTSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL3882276 | 0.83 | ACHE (0.39) | TSHRCYP2A6ALDH1A1CA1CA2 | |
| SCHEMBL6312811 | 0.81 | TRPA1 (0.32) | TRPA1ATMTSHRSMN1; SMN2 | |
| SCHEMBL3676327 | 0.78 | TRPA1 (0.42) | TRPA1ATMTSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL6312471 | 0.76 | TRPA1 (0.41) | TRPA1ATMTSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL11196291 | 0.72 | TRPA1 (0.38) | TRPA1ATMTSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL3190512 | 0.72 | TRPA1 (0.46) | TRPA1ATMTSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL31005149 | 0.72 | TRPA1 (0.46) | TRPA1ATMTSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL777552 | 0.70 | ACHE (0.37) | ACHE | |
| SCHEMBL775886 | 0.69 | CES2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1288222-C | Phosphorescent light-emitting material | LAIDE SCIENCE & TECHNOLOGY CO (CN) | 2006-12-06 | — | — | CN | claimed |
| US-6838019-B2 | Phosphorescent material and electroluminescent device using thereof | RITEK CORPORATION (TW) | 2005-01-04 | — | — | US | claimed |
| CN-1464027-A | Phosphorescent light-emitting material | LAIDE SCIENCE & TECHNOLOGY CO (CN) | 2003-12-31 | — | — | CN | claimed |
| US-20030102800-A1 | Phosphorescent material | RITEK CORPORATION (TW) | 2003-06-05 | — | — | US | claimed |
| CN-1288222-C | Phosphorescent light-emitting material | LAIDE SCIENCE & TECHNOLOGY CO (CN) | 2006-12-06 | — | — | CN | disclosed |
| US-6969726-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-11-29 | — | — | US | disclosed |
| US-6838019-B2 | Phosphorescent material and electroluminescent device using thereof | RITEK CORPORATION (TW) | 2005-01-04 | — | — | US | disclosed |
| CN-1464027-A | Phosphorescent light-emitting material | LAIDE SCIENCE & TECHNOLOGY CO (CN) | 2003-12-31 | — | — | CN | disclosed |
| US-20030102800-A1 | Phosphorescent material | RITEK CORPORATION (TW) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030102800-A1 | Phosphorescent material | PKD1, RPS6KA1, RPS6KA6 | TRPA1 852/4885ATM 1988/4885TSHR 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.